Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials: 2016-2025

Historic Raw Materials for Heron Therapeutics (HRTX) over the last 8 years, with Sep 2025 value amounting to $32.8 million.

  • Heron Therapeutics' Raw Materials rose 57.46% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 57.46%. This contributed to the annual value of $19.7 million for FY2024, which is 11.85% up from last year.
  • Latest data reveals that Heron Therapeutics reported Raw Materials of $32.8 million as of Q3 2025, which was down 8.47% from $35.8 million recorded in Q2 2025.
  • Heron Therapeutics' Raw Materials' 5-year high stood at $35.8 million during Q2 2025, with a 5-year trough of $15.1 million in Q4 2022.
  • In the last 3 years, Heron Therapeutics' Raw Materials had a median value of $19.5 million in 2025 and averaged $21.3 million.
  • In the last 5 years, Heron Therapeutics' Raw Materials crashed by 36.02% in 2023 and then skyrocketed by 82.80% in 2025.
  • Over the past 5 years, Heron Therapeutics' Raw Materials (Quarterly) stood at $21.2 million in 2021, then declined by 28.58% to $15.1 million in 2022, then climbed by 16.56% to $17.6 million in 2023, then grew by 11.85% to $19.7 million in 2024, then skyrocketed by 57.46% to $32.8 million in 2025.
  • Its last three reported values are $32.8 million in Q3 2025, $35.8 million for Q2 2025, and $19.5 million during Q1 2025.